Burning Rock Biotech (BNR) Receivables (2019 - 2026)

Burning Rock Biotech (BNR) has reported Receivables for 8 consecutive years, with $25.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables rose 5.29% year-over-year to $25.6 million; the TTM figure through Mar 2026 stood at $25.6 million (up 5.29% YoY), while the FY2025 annual figure was $26.0 million, down 10.32% from the prior year.
• Receivables came in at $25.6 million for Q1 2026 at Burning Rock Biotech, roughly flat from $25.6 million in the prior quarter.
• The five-year high for Receivables was $28.3 million in Q2 2025, with the low at $15.3 million in Q2 2022.
• Average Receivables over 5 years is $24.1 million, with a median of $24.3 million recorded in 2025.
• Across the five-year window, Receivables surged 99.97% in 2022 and fell 13.95% in 2024, its largest moves.
• Year by year, Receivables stood at $21.3 million in 2022, then fell by 2.59% to $20.8 million in 2023, then gained by 11.13% to $23.1 million in 2024, then gained by 11.07% to $25.6 million in 2025, then fell by 0.25% to $25.6 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $25.6 million, $25.6 million, and $27.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.